Matthew Bryan Beare, MD
Family Practice · Bakersfield
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 10 years
- Graduated 2016
Offices
2 locations · Clinica Sierra Vista · 180 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Beare’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A159055 · Current
Licensed to practise in California · since 2018 · expires 2028-10-31 · Ross University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Family Medicine - Family Medicine
- American Board of Preventive Medicine - Addiction Medicine
Medicaid work
$1,597,251 in 2024
Medicaid paid $1,597,251 for 18,023 billed services this clinician did in 2024, up to 708 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Other specified case management service not elsewhere classified | 6,269 | $714,348 |
| Clinic visit/encounter, all-inclusive | 2,720 | $459,370 |
| Return visit (30+ min) | 4,590 | $254,995 |
| Coordinated care fee, physician coordinated care oversight services | 1,543 | $139,348 |
| New patient visit (45+ min) | 116 | $11,325 |
| Coordinated care fee, scheduled team conference | 201 | $9,885 |
| Short return visit (20+ min) | 164 | $7,980 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 744 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 231 | $0 |
| Most recent systolic blood pressure greater than or equal to 140 mm Hg (HTN, CKD, CAD) (DM) | 223 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 573 | $0 |
| Most recent diastolic blood pressure 80-89 mm Hg (HTN, CKD, CAD) (DM) | 460 | $0 |
| 2024 | 18,023 | 13 | 708 | $1,597,251 |
| 2023 | 9,339 | 10 | 230 | $414,634 |
| 2022 | 7,348 | 10 | 234 | $302,276 |
| 2021 | 15,938 | 32 | 401 | $742,015 |
| 2020 | 9,903 | 21 | 281 | $420,598 |
| 2019 | 2,696 | 20 | 121 | $98,428 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 2,726 | $324,742 |
| Return visit (30+ min) | 4,498 | $80,873 |
| Short return visit (20+ min) | 341 | $6,052 |
| New patient visit (45+ min) | 81 | $2,967 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 531 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 188 | $0 |
| Most recent systolic blood pressure greater than or equal to 140 mm Hg (HTN, CKD, CAD) (DM) | 151 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 427 | $0 |
| Most recent diastolic blood pressure 80-89 mm Hg (HTN, CKD, CAD) (DM) | 292 | $0 |
| Most recent diastolic blood pressure greater than or equal to 90 mm Hg (HTN, CKD, CAD) (DM) | 104 | $0 |
2022
| Clinic visit/encounter, all-inclusive | 2,433 | $213,628 |
| Return visit (30+ min) | 4,069 | $72,072 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) | 161 | $5,852 |
| Short return visit (20+ min) | 297 | $4,792 |
| New patient visit (45+ min) | 154 | $4,095 |
| OFF/OP EST MAY X REQ PHY/QHP | 110 | $1,820 |
| Short return visit | 18 | $18 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 61 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 32 | $0 |
| Most recent diastolic blood pressure 80-89 mm Hg (HTN, CKD, CAD) (DM) | 13 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 5,705 | $600,631 |
| Return visit (30+ min) | 5,644 | $79,464 |
| Short return visit (20+ min) | 1,648 | $19,332 |
| Short return visit | 1,228 | $9,722 |
| New patient visit (45+ min) | 356 | $8,337 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 18-39 years | 98 | $4,247 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) | 109 | $3,971 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; first dose | 83 | $1,943 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; second dose | 37 | $1,943 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 40-64 years | 27 | $1,544 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; first dose | 24 | $1,474 |
| OFF/OP EST MAY X REQ PHY/QHP | 114 | $1,436 |
2020
| Clinic visit/encounter, all-inclusive | 3,467 | $328,017 |
| Return visit (30+ min) | 3,848 | $60,816 |
| New patient visit (45+ min) | 372 | $10,209 |
| Short return visit (20+ min) | 585 | $7,971 |
| Short return visit | 642 | $7,144 |
| PSYCH DIAGNOSTIC EVALUATION | 24 | $1,921 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 89 | $1,019 |
| ACUTE HEPATITIS PANEL | 18 | $752 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 20 | $623 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 20 | $621 |
| OFF/OP EST MAY X REQ PHY/QHP | 57 | $427 |
| Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result | 17 | $344 |
2019
| Clinic visit/encounter, all-inclusive | 631 | $59,527 |
| Return visit (30+ min) | 1,002 | $21,283 |
| New patient visit (45+ min) | 89 | $4,463 |
| ACUTE HEPATITIS PANEL | 77 | $3,139 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 80 | $2,435 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 80 | $2,427 |
| Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result | 78 | $1,542 |
| Hemoglobin A1C level | 92 | $777 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 35 | $535 |
| COMPREHENSIVE METABOLIC PANEL | 40 | $474 |
| Short return visit (20+ min) | 12 | $395 |
| Syphilis test, non-treponemal antibody; qualitative (eg, VDRL, RPR, ART) | 93 | $350 |
Drugs they prescribed that Part D paid
$309,401
Pharmacies billed $309,401 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 8% of their Part D prescriptions (86 of 1,105) in 2024. A higher opioid share than 9 in 10 peers; the typical family practice clinician is at 2%. Long-acting opioids: 37% of their opioid prescriptions.
992 generic and 113 brand-name prescriptions · $309,401 in drug cost · 19 antibiotic prescriptions to 11 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Buprenorphine-Naloxone | 140 | $25,241 | $180 |
| Eliquis | 13 | $7,215 | $555 |
| Spiriva Handihaler | 12 | $6,343 | $529 |
| Buprenorphine | 28 | $1,877 | $67 |
| Dextroamphetamine Sulfate | 12 | $922 | $77 |
See all 28 drugs
| Buprenorphine-Naloxone | 140 | $25,241 | $180 |
| Eliquis | 13 | $7,215 | $555 |
| Spiriva Handihaler | 12 | $6,343 | $529 |
| Buprenorphine | 28 | $1,877 | $67 |
| Dextroamphetamine Sulfate | 12 | $922 | $77 |
| Albuterol Sulfate Hfa | 28 | $783 | $28 |
| Hydrocodone-Acetaminophen | 27 | $610 | $23 |
| Gabapentin | 31 | $578 | $19 |
| Ibuprofen | 54 | $388 | $7 |
| Bupropion Hcl Sr | 25 | $386 | $15 |
| Quetiapine | 17 | $284 | $17 |
| Methadone | 14 | $195 | $14 |
| Lisinopril | 38 | $185 | $5 |
| Omeprazole | 23 | $178 | $8 |
| Buspirone | 18 | $171 | $10 |
| Levothyroxine | 19 | $160 | $8 |
| Atorvastatin | 40 | $149 | $4 |
| Tamsulosin | 31 | $143 | $5 |
| Junel Fe | 11 | $143 | $13 |
| Pantoprazole | 19 | $130 | $7 |
| Tramadol | 24 | $127 | $5 |
| Famotidine | 17 | $117 | $7 |
| Amlodipine Besylate | 15 | $64 | $4 |
| Temazepam | 12 | $58 | $5 |
| Carvedilol | 12 | $42 | $4 |
| Trazodone | 12 | $36 | $3 |
| Lorazepam | 14 | $29 | $2 |
| Hydrochlorothiazide | 13 | $25 | $2 |
Year by year
| 2024 | 1,105 | 99 | 8% (86) | 10% | $309,401 |
| 2023 | 1,554 | 127 | 3% (52) | None | $415,406 |
| 2022 | 1,843 | 147 | 3% (55) | 15% | $368,026 |
| 2021 | 1,354 | 110 | 5% (63) | None | $124,121 |
| 2020 | 1,162 | 120 | 4% (44) | None | $92,008 |
| 2019 | 786 | 131 | 3% (20) | None | $35,539 |
| 2018 | 249 | 47 | 0% (0) | None | $11,499 |
| 2017 | 65 | 17 | 0% (0) | None | $4,059 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 41 drugs
| Austedo | 21 | $136,238 | $6,488 |
| Buprenorphine-Naloxone | 120 | $37,440 | $312 |
| Zubsolv | 12 | $14,492 | $1,208 |
| Spiriva Handihaler | 18 | $13,889 | $772 |
| Suboxone | 18 | $10,555 | $586 |
| Symbicort | 13 | $5,580 | $429 |
| Anoro Ellipta | 11 | $5,511 | $501 |
| Buprenorphine | 26 | $2,800 | $108 |
| Acamprosate | 13 | $1,716 | $132 |
| Albuterol Sulfate Hfa | 44 | $1,440 | $33 |
| Tamsulosin | 56 | $1,308 | $23 |
| Atorvastatin | 83 | $1,127 | $14 |
| Gabapentin | 54 | $1,124 | $21 |
| Lisinopril | 62 | $1,072 | $17 |
| Bupropion Hcl Sr | 26 | $1,002 | $39 |
| Buspirone | 29 | $985 | $34 |
| Duloxetine | 16 | $827 | $52 |
| Famotidine | 29 | $652 | $22 |
| Quetiapine | 20 | $577 | $29 |
| Pantoprazole | 38 | $509 | $13 |
| Hydrocodone-Acetaminophen | 19 | $485 | $26 |
| Metformin | 41 | $485 | $12 |
| Temazepam | 13 | $477 | $37 |
| Ibuprofen | 44 | $472 | $11 |
| Trazodone | 27 | $448 | $17 |
| Levothyroxine | 40 | $435 | $11 |
| Amlodipine Besylate | 32 | $403 | $13 |
| Fluticasone Propionate | 13 | $371 | $29 |
| Rosuvastatin | 12 | $368 | $31 |
| Losartan | 25 | $366 | $15 |
| Hydroxyzine | 21 | $317 | $15 |
| Omeprazole | 31 | $316 | $10 |
| Sumatriptan | 12 | $309 | $26 |
| Ondansetron Odt | 14 | $302 | $22 |
| Topiramate | 11 | $237 | $22 |
| Citalopram Hbr | 14 | $200 | $14 |
| Junel Fe | 13 | $169 | $13 |
| Tramadol | 14 | $144 | $10 |
| Furosemide | 11 | $132 | $12 |
| Hydrochlorothiazide | 21 | $68 | $3 |
| Cyclobenzaprine | 11 | $61 | $6 |
2022: 40 drugs
| Buprenorphine-Naloxone | 97 | $33,713 | $348 |
| Zubsolv | 17 | $15,932 | $937 |
| Spiriva Handihaler | 13 | $10,459 | $805 |
| Albuterol Sulfate Hfa | 75 | $3,604 | $48 |
| Atorvastatin | 146 | $1,617 | $11 |
| Gabapentin | 80 | $1,193 | $15 |
| Lisinopril | 93 | $794 | $9 |
| Chlorthalidone | 17 | $794 | $47 |
| Tamsulosin | 63 | $770 | $12 |
| Tramadol | 22 | $719 | $33 |
| Pregabalin | 17 | $657 | $39 |
| Losartan | 50 | $542 | $11 |
| Levothyroxine | 49 | $538 | $11 |
| Hydroxyzine | 41 | $516 | $13 |
| Pantoprazole | 63 | $492 | $8 |
| Diclofenac | 11 | $373 | $34 |
| Famotidine | 34 | $335 | $10 |
| Metformin | 53 | $329 | $6 |
| Temazepam | 13 | $301 | $23 |
| Ondansetron Odt | 13 | $245 | $19 |
| Naproxen | 37 | $241 | $7 |
| Bupropion Hcl Sr | 14 | $231 | $16 |
| Duloxetine | 16 | $224 | $14 |
| Hydrocodone-Acetaminophen | 13 | $221 | $17 |
| Omeprazole | 24 | $219 | $9 |
| Rosuvastatin | 13 | $195 | $15 |
| Fluticasone Propionate | 18 | $178 | $10 |
| Trazodone | 24 | $178 | $7 |
| Pravastatin | 12 | $170 | $14 |
| Ibuprofen | 28 | $162 | $6 |
| Amlodipine Besylate | 35 | $139 | $4 |
| Simvastatin | 11 | $132 | $12 |
| Meloxicam | 20 | $101 | $5 |
| Metoprolol | 17 | $100 | $6 |
| Hydrochlorothiazide | 39 | $100 | $3 |
| Clopidogrel | 11 | $90 | $8 |
| Furosemide | 12 | $79 | $7 |
| Buspirone | 16 | $62 | $4 |
| Quetiapine | 12 | $51 | $4 |
| Cyclobenzaprine | 12 | $45 | $4 |
2021: 39 drugs
| Buprenorphine-Naloxone | 61 | $18,370 | $301 |
| Toujeo Max Solostar | 15 | $12,874 | $858 |
| Zubsolv | 15 | $10,994 | $733 |
| Belbuca | 14 | $10,432 | $745 |
| Suboxone | 14 | $10,048 | $718 |
| Anoro Ellipta | 14 | $6,390 | $456 |
| Albuterol Sulfate Hfa | 51 | $2,094 | $41 |
| Atorvastatin | 115 | $1,678 | $15 |
| Gabapentin | 52 | $980 | $19 |
| Levothyroxine | 33 | $742 | $22 |
| Tamsulosin | 48 | $716 | $15 |
| Lisinopril | 82 | $557 | $7 |
| Chlorthalidone | 12 | $381 | $32 |
| Hydrocodone-Acetaminophen | 11 | $376 | $34 |
| Pantoprazole | 38 | $316 | $8 |
| Losartan | 33 | $287 | $9 |
| Carbidopa-Levodopa Er | 12 | $252 | $21 |
| Trazodone | 25 | $247 | $10 |
| Carbidopa-Levodopa | 13 | $231 | $18 |
| Metformin | 54 | $228 | $4 |
| Cyclobenzaprine | 15 | $168 | $11 |
| Tramadol | 23 | $168 | $7 |
| Omeprazole | 18 | $153 | $8 |
| Naproxen | 23 | $152 | $7 |
| Fluticasone Propionate | 13 | $144 | $11 |
| Simvastatin | 13 | $137 | $11 |
| Hydroxyzine | 15 | $135 | $9 |
| Amlodipine Besylate | 32 | $114 | $4 |
| Doxazosin Mesylate | 12 | $107 | $9 |
| Metoprolol | 20 | $83 | $4 |
| Hydrochlorothiazide | 22 | $73 | $3 |
| Ibuprofen | 13 | $71 | $5 |
| Metformin Hcl Er | 16 | $69 | $4 |
| Furosemide | 11 | $65 | $6 |
| Finasteride | 11 | $64 | $6 |
| Methadone | 11 | $62 | $6 |
| Temazepam | 12 | $52 | $4 |
| Glipizide | 11 | $37 | $3 |
| Metoclopramide | 11 | $32 | $3 |
2020: 25 drugs
| Jardiance | 12 | $11,861 | $988 |
| Buprenorphine-Naloxone | 43 | $11,364 | $264 |
| Albuterol Sulfate Hfa | 25 | $1,305 | $52 |
| Atorvastatin | 107 | $1,220 | $11 |
| Gabapentin | 45 | $653 | $15 |
| Hydrocodone-Acetaminophen | 19 | $444 | $23 |
| Chlorthalidone | 11 | $358 | $33 |
| Levothyroxine | 17 | $340 | $20 |
| Lisinopril | 79 | $334 | $4 |
| Tamsulosin | 25 | $332 | $13 |
| Losartan | 40 | $312 | $8 |
| Metformin | 59 | $309 | $5 |
| Trazodone | 33 | $247 | $7 |
| Pantoprazole | 32 | $235 | $7 |
| Omeprazole | 28 | $198 | $7 |
| Amlodipine Besylate | 35 | $128 | $4 |
| Naproxen | 22 | $123 | $6 |
| Ibuprofen | 13 | $121 | $9 |
| Hydroxyzine | 11 | $102 | $9 |
| Cyclobenzaprine | 17 | $101 | $6 |
| Simvastatin | 16 | $82 | $5 |
| Metoprolol | 15 | $75 | $5 |
| Finasteride | 11 | $50 | $5 |
| Fluoxetine | 12 | $34 | $3 |
| Metformin Hcl Er | 12 | $22 | $2 |
2019: 20 drugs
| Ventolin Hfa | 22 | $1,228 | $56 |
| Atorvastatin | 53 | $720 | $14 |
| Levothyroxine | 33 | $610 | $18 |
| Chlorthalidone | 12 | $423 | $35 |
| Lisinopril | 69 | $355 | $5 |
| Gabapentin | 37 | $295 | $8 |
| Metformin | 52 | $291 | $6 |
| Amlodipine Besylate | 35 | $234 | $7 |
| Fluticasone Propionate | 12 | $233 | $19 |
| Pantoprazole | 34 | $232 | $7 |
| Tamsulosin | 11 | $219 | $20 |
| Losartan | 25 | $172 | $7 |
| Diclofenac | 11 | $164 | $15 |
| Naproxen | 18 | $139 | $8 |
| Omeprazole | 19 | $134 | $7 |
| Simvastatin | 29 | $109 | $4 |
| Hydrochlorothiazide | 15 | $69 | $5 |
| Glipizide | 13 | $67 | $5 |
| Metformin Hcl Er | 12 | $34 | $3 |
| Meloxicam | 15 | $31 | $2 |
2018: 7 drugs
| Ventolin Hfa | 11 | $597 | $54 |
| Atorvastatin | 27 | $354 | $13 |
| Lisinopril | 33 | $98 | $3 |
| Gabapentin | 14 | $92 | $7 |
| Metformin | 24 | $65 | $3 |
| Simvastatin | 14 | $27 | $2 |
| Hydrochlorothiazide | 12 | $14 | $1 |
Money from drug and device companies
$16,594 in 2025
| 2025 | 13 | 78 | $14,025 | $16,594 |
| 2024 | 7 | 69 | $28,118 | $33,939 |
| 2023 | 8 | 84 | $39,140 | $47,057 |
| 2022 | 5 | 18 | None | $483 |
| 2021 | 1 | 1 | None | $18 |
| 2020 | 3 | 3 | None | $90 |
| 2019 | 4 | 4 | None | $82 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Mavyret | $9,612 | 23 payments
|
| Gilead Sciences | Epclusa | $6,282 | 24 payments
|
| ViiV Healthcare | Apretude | $177 | 8 payments
|
| Braeburn | Brixadi | $176 | 7 payments
|
| Indivior | Sublocade | $138 | 6 payments
|
| Alkermes | Vivitrol | $48 | 2 payments
|
See all 78 published payments
| Gilead Sciences | Meals · 2025-12-15 | None | $24 |
| Abbvie | Paid to speak or teach · 2025-12-11 | Mavyret | $1,875 |
| Abbvie | Meals · 2025-12-09 | Mavyret | $1 |
| Abbvie | Meals · 2025-12-08 | Mavyret | $8 |
| Braeburn | Meals · 2025-12-05 | Brixadi | $20 |
| Gilead Sciences | Meals · 2025-12-04 | None | $11 |
| Indivior | Meals · 2025-12-03 | Sublocade | $27 |
| Gilead Sciences | Meals · 2025-11-21 | None | $4 |
| Alkermes | Meals · 2025-11-19 | Vivitrol | $20 |
| ViiV Healthcare | Meals · 2025-11-18 | Apretude | $17 |
| Abbvie | Meals · 2025-11-18 | Mavyret | $125 |
| Gilead Sciences | Meals · 2025-11-12 | Biktarvy | $8 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-04 | Cobenfy | $16 |
| Gilead Sciences | Meals · 2025-10-31 | None | $2 |
| Gilead Sciences | Meals · 2025-10-28 | None | $21 |
| Indivior | Meals · 2025-10-28 | Sublocade | $20 |
| Gilead Sciences | Paid to speak or teach · 2025-10-24 | Epclusa | $600 |
| Braeburn | Meals · 2025-10-14 | Brixadi | $26 |
| Gilead Sciences | Meals · 2025-09-18 | None | $7 |
| Gilead Sciences | Meals · 2025-09-17 | None | $21 |
| Indivior | Meals · 2025-09-17 | Sublocade | $14 |
| Abbvie | Meals · 2025-09-15 | Mavyret | $19 |
| ViiV Healthcare | Meals · 2025-09-09 | Apretude | $23 |
| Abbvie | Meals · 2025-09-02 | Mavyret | $6 |
| Braeburn | Meals · 2025-08-28 | Brixadi | $15 |
| Alkermes | Meals · 2025-08-19 | Vivitrol | $28 |
| Gilead Sciences | Meals · 2025-08-14 | None | $16 |
| ViiV Healthcare | Meals · 2025-08-08 | Apretude | $27 |
| Exact Sciences | Meals · 2025-08-08 | Cologuard Collection Kit | $27 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-08-05 | Kerendia | $18 |
| Pfizer | Meals · 2025-08-05 | Prevnar 20 | $20 |
| ViiV Healthcare | Meals · 2025-08-04 | Apretude | $17 |
| Gilead Sciences | Paid to speak or teach · 2025-07-31 | Epclusa | $1,050 |
| Indivior | Meals · 2025-07-31 | Sublocade | $27 |
| Abbvie | Paid to speak or teach · 2025-07-30 | Mavyret | $3,000 |
| ViiV Healthcare | Meals · 2025-07-29 | Apretude | $20 |
| Gilead Sciences | Meals · 2025-07-17 | None | $5 |
| Abbvie | Paid to speak or teach · 2025-07-16 | Mavyret | $1,875 |
| Abbvie | Travel · 2025-07-11 | Mavyret | $346 |
| Abbvie | Meals · 2025-07-11 | Mavyret | $60 |
| Abbvie | Meals · 2025-07-11 | Mavyret | $25 |
| Abbvie | Meals · 2025-07-11 | Mavyret | $70 |
| Abbvie | Meals · 2025-07-11 | Mavyret | $25 |
| Abbvie | Meals · 2025-07-11 | Mavyret | $150 |
| Braeburn | Meals · 2025-07-08 | Brixadi | $15 |
| Abbvie | Meals · 2025-06-25 | Mavyret | $18 |
| Hologic Sales and Service | Meals · 2025-06-17 | Aptima | $25 |
| Lilly USA | Meals · 2025-06-10 | Mounjaro | $15 |
| Gilead Sciences | Meals · 2025-06-03 | None | $35 |
| Gilead Sciences | Paid to speak or teach · 2025-06-02 | Epclusa | $1,050 |
| ViiV Healthcare | Meals · 2025-05-29 | Apretude | $26 |
| Indivior | Meals · 2025-05-27 | Sublocade | $21 |
| ViiV Healthcare | Meals · 2025-05-20 | Apretude | $23 |
| Gilead Sciences | Meals · 2025-05-13 | None | $2 |
| Gilead Sciences | Travel · 2025-04-30 | Epclusa | $185 |
| Lilly USA | Meals · 2025-04-29 | Mounjaro | $17 |
| Braeburn | Meals · 2025-04-28 | Brixadi | $16 |
| Gilead Sciences | Meals · 2025-04-25 | None | $74 |
| Braeburn | Meals · 2025-04-24 | Brixadi | $65 |
| Gilead Sciences | Paid to speak or teach · 2025-04-23 | Epclusa | $2,700 |
| Abbvie | Meals · 2025-04-15 | Mavyret | $23 |
| Gilead Sciences | Meals · 2025-04-11 | None | $34 |
| Abbvie | Meals · 2025-04-10 | Mavyret | $16 |
| Gilead Sciences | Travel · 2025-04-08 | Epclusa | $244 |
| Gilead Sciences | Meals · 2025-04-08 | Epclusa | $123 |
| Braeburn | Meals · 2025-03-19 | Brixadi | $19 |
| Gilead Sciences | Meals · 2025-03-13 | None | $6 |
| Abbvie | Meals · 2025-03-11 | Mavyret | $14 |
| Gilead Sciences | Meals · 2025-03-05 | None | $32 |
| ViiV Healthcare | Meals · 2025-03-03 | Apretude | $24 |
| Indivior | Meals · 2025-02-26 | Sublocade | $29 |
| Abbvie | Meals · 2025-02-17 | Mavyret | $14 |
| Abbvie | Meals · 2025-02-11 | Mavyret | $23 |
| Dynavax Technologies | Meals · 2025-02-04 | Heplisav-B | $22 |
| Abbvie | Paid to speak or teach · 2025-02-04 | Mavyret | $1,875 |
| Gilead Sciences | Meals · 2025-02-04 | None | $29 |
| Abbvie | Meals · 2025-01-28 | Mavyret | $29 |
| Abbvie | Meals · 2025-01-24 | Mavyret | $15 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $33,939
| Gilead Sciences | Epclusa | $26,402 | 41 payments
|
| Braeburn | Brixadi | $5,416 | 13 payments
|
| Abbvie | Mavyret | $1,995 | 9 payments
|
| ViiV Healthcare | Apretude | $54 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Cobenfy | $27 | 1 payment
|
| Merck Sharp & Dohme | Pifeltro | $23 | 1 payment
|
| Novo Nordisk | Rybelsus | $22 | 1 payment
|
2023: $47,057
| Gilead Sciences | Epclusa | $35,555 | 52 payments
|
| AbbVie | Mavyret | $11,116 | 18 payments
|
| Merck Sharp & Dohme | Pifeltro | $120 | 5 payments
|
| Braeburn | Brixadi | $114 | 2 payments
|
| ViiV Healthcare | Apretude | $110 | 4 payments
|
| Novo Nordisk | Ozempic | $15 | 1 payment
|
| Teva Pharmaceuticals USA | Austedo Xr | $14 | 1 payment
|
| Indivior | Sublocade | $14 | 1 payment
|
2022: $483
| Abbvie | Mavyret | $334 | 10 payments
|
| Gilead Sciences | None | $94 | 5 payments
|
| Indivior | Sublocade | $22 | 1 payment
|
| Teva Pharmaceuticals USA | Austedo | $18 | 1 payment
|
| ViiV Healthcare | Apretude | $16 | 1 payment
|
2021: $18
| Indivior | Sublocade | $18 | 1 payment
|
2020: $90
| AbbVie | Mavyret | $48 | 1 payment
|
| Smith+Nephew | Stravix | $21 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $20 | 1 payment
|
2019: $82
| Smith+Nephew | Stravix | $33 | 1 payment
|
| Dynavax Technologies | Heplisav-B | $17 | 1 payment
|
| GlaxoSmithKline | Bexsero | $16 | 1 payment
|
| Merck Sharp & Dohme | Januvia | $15 | 1 payment
|
Professional record
- NPI
- 1326400052
- Licence
- CA A159055California A159055: Current · expires 2028-10-31
- Group
- Clinica Sierra Vista
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Family medicine (207Q00000X)
- Mailing address
- 301 Brundage Ln, Bakersfield, CA, 93304
- NPI first listed
- 2016-03-22
- NPI last updated
- 2025-01-06
- NPI record certified
- 2025-01-06
This is when the NPI record was last certified, not a medical board exam.